Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 2/20 | 1.00 |
| ▸ | IL6 | P05231 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381054 | 1.00 | TLR7 (1.00) | TLR7NUDT1IL6 | |
| SCHEMBL1146177 | 0.92 | TLR7 (0.85) | TLR7NUDT1IL6 | |
| SCHEMBL4124603 | 0.91 | TLR7 (0.84) | TLR7NUDT1IL6 | |
| SCHEMBL43878 | 0.90 | TLR7 (0.82) | TLR7NUDT1IL6 | |
| SCHEMBL29997135 | 0.90 | TLR7 (0.82) | TLR7NUDT1IL6 | |
| SCHEMBL1146207 | 0.90 | TLR7 (0.80) | TLR7NUDT1IL6 | |
| SCHEMBL20740720 | 0.89 | TLR7 (1.00) | TLR7NUDT1IL6 | |
| SCHEMBL1146185 | 0.89 | TLR7 (0.79) | TLR7NUDT1IL6 | |
| SCHEMBL4140913 | 0.89 | TLR7 (0.79) | TLR7NUDT1IL6 | |
| SCHEMBL1146727 | 0.89 | TLR7 (0.79) | TLR7NUDT1IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024308-A1 | TLR7/8 ANTAGONISTS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20220251212-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-08-11 | — | — | US | disclosed |
| US-20220204641-A1 | ANTI-CD20 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-06-30 | — | — | US | disclosed |
| US-20220175762-A1 | IMMUNE MODULATORY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-06-09 | — | — | US | disclosed |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-02-03 | — | — | US | disclosed |
| US-11220552-B2 | Anti-CD20 combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-01-11 | — | — | US | disclosed |
| US-20210363271-A1 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-11-25 | — | — | US | disclosed |
| US-11136397-B2 | Anti-EGFR combinations for treating tumors | BIRDIE PHARMACEUTICALS, INC. (KY) | 2021-10-05 | — | — | US | disclosed |
| US-11130812-B2 | Anti PD-L1 conjugates for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-09-28 | — | — | US | disclosed |
| US-11046781-B2 | Anti-HER2 combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-06-29 | — | — | US | disclosed |
| US-20190002583-A1 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2019-01-03 | — | — | US | disclosed |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-10-12 | — | — | US | disclosed |
| US-20170114137-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170056391-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-03-02 | — | — | US | disclosed |
| US-8846697-B2 | Purine analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2700638-A1 | Purine analogs | The Regents Of the University of California (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20130190494-A1 | PURINE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-25 | — | — | US | disclosed |
| US-20110098294-A1 | PURINE ANALOGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-28 | — | — | US | disclosed |
| EP-2029597-A2 | PURINE ANALOGS | The Regents of the University of California (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007142755-A2 | PURINE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114137-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | PDCD1LG2, CD274, PDCD1 | TLR7 879/4885NUDT1 3947/4885IL6 1303/4885 |
| US-11046781-B2 | Anti-HER2 combinations for treating tumors | ERBB2, FCGR2A, FCER2 | TLR7 309/4885NUDT1 3974/4885IL6 2651/4885 |
| US-20240024308-A1 | TLR7/8 ANTAGONISTS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | TLR7, TLR8, TLR9 | TLR7 1/4885NUDT1 1605/4885IL6 220/4885 |
| US-20110098294-A1 | PURINE ANALOGS | PNP, HPRT1, NT5C2 | TLR7 660/4885NUDT1 4/4885IL6 2160/4885 |
| US-20170056391-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | TP53, MCL1, MSH2 | TLR7 1537/4885NUDT1 1375/4885IL6 481/4885 |
| US-20190002583-A1 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | ERBB2, FCGR2A, FCER2 | TLR7 309/4885NUDT1 3974/4885IL6 2651/4885 |
| US-20210363271-A1 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | ERBB2, EGFR, ERBB3 | TLR7 1770/4885NUDT1 4071/4885IL6 2558/4885 |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | TLR7 883/4885NUDT1 4325/4885IL6 2322/4885 |
| US-11220552-B2 | Anti-CD20 combinations for treating tumors | CD209, CD68, CD47 | TLR7 1058/4885NUDT1 4485/4885IL6 1049/4885 |
| US-11136397-B2 | Anti-EGFR combinations for treating tumors | EGFR, ERBB3, ERBB2 | TLR7 2007/4885NUDT1 3504/4885IL6 2580/4885 |
| US-20220175762-A1 | IMMUNE MODULATORY COMPOSITIONS AND METHODS FOR TREATING CANCERS | IFNG, CD47, CD74 | TLR7 75/4885NUDT1 3300/4885IL6 452/4885 |
| US-20130190494-A1 | PURINE ANALOGS | PNP, HPRT1, NT5C2 | TLR7 1214/4885NUDT1 4/4885IL6 1820/4885 |
| US-11130812-B2 | Anti PD-L1 conjugates for treating tumors | CD274, PDCD1LG2, PDCD1 | TLR7 980/4885NUDT1 4518/4885IL6 2390/4885 |
| US-20220204641-A1 | ANTI-CD20 COMBINATIONS FOR TREATING TUMORS | CD209, CD68, CD47 | TLR7 1058/4885NUDT1 4485/4885IL6 1049/4885 |
| US-20220251212-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | PDCD1LG2, CD274, PDCD1 | TLR7 879/4885NUDT1 3947/4885IL6 1303/4885 |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | TLR7 980/4885NUDT1 4518/4885IL6 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.